Ernexa Therapeutics (ERNAW) Gains from Investment Securities (2011 - 2025)
Ernexa Therapeutics' (ERNAW) quarterly Gains from Investment Securities came in at -$1000.0 in Q1 2025, down 101.43% YoY from $70000.0 in Q1 2024, and up 99.88% on a QoQ basis from -$831000.0 in Q3 2024.
Powered by 
Analysis
Ernexa Therapeutics (ERNAW) Gains from Investment Securities (2011 - 2025) Analysis & Trends
Ernexa Therapeutics (ERNAW) has 7 years of Gains from Investment Securities data on file, last reported at -$1000.0 in Q1 2025.
- Quarterly Gains from Investment Securities fell 101.43% year-over-year to -$1000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was -$1000.0 (up 99.89% YoY) and the FY2025 annual result came in at -$1000.0, down 101.52% from the prior year.
- Gains from Investment Securities rose to -$1000.0 in Q1 2025, from -$831000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $570000.0 in Q4 2021 to a low of -$1.0 million in Q3 2022.
- A 5-year average of -$201384.6 and a median of -$49000.0 in 2023 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities surged 98.04% — and 2024, when it slumped 4055.0%.
- Tracing ERNAW's Gains from Investment Securities over 5 years: stood at $570000.0 in 2021, then slumped by 152.98% to -$302000.0 in 2022, then jumped by 83.77% to -$49000.0 in 2023, then slumped by 1595.92% to -$831000.0 in 2024, then jumped by 99.88% to -$1000.0 in 2025.
- The last three Gains from Investment Securities figures came in at -$1000.0 (Q1 2025), -$831000.0 (Q3 2024), and -$136000.0 (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ernexa Therapeutics | 67,312.70 | 67,312.70 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | -1,000.00 |
| Dec 31, 2024 | 483,000.00 |
| Sep 30, 2024 | -831,000.00 |
| Jun 30, 2024 | -136,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Dec 31, 2023 | -49,000.00 |
| Sep 30, 2023 | -20,000.00 |
| Jun 30, 2023 | -191,000.00 |
| Mar 31, 2023 | 45,000.00 |
| Dec 31, 2022 | -302,000.00 |
| Sep 30, 2022 | -1.02 Mn |
| Dec 31, 2021 | 570,000.00 |
| Sep 30, 2021 | 70,000.00 |
| Mar 31, 2021 | -820,000.00 |
| Dec 31, 2020 | 19.24 Mn |
| Sep 30, 2011 | 12,000.00 |